Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  IRLAB Therapeutics AB (publ)    IRLAB A   SE0012675361


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

IRLAB Therapeutics publ : clinical drug candidate IRL752 published in JPET

share with twitter share with LinkedIn share with facebook
07/09/2020 | 03:16am EDT

IRLAB announced today that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of impaired balance and falls in Parkinson's disease, is accepted and published online in the Journal of Pharmacology and Experimental Therapeutics, JPET.

"This paper was the result of a successful cross-disciplinary collaboration between scientists at IRLAB and an academic research group in the UK. To share our research within an international network and explore the potential of our drug candidate in a renowned independent lab, specialized in studies of cognitive processes, is significant for us. I would also like to emphasize the importance of these scientific findings for the continued clinical development and, ultimately, the change we hope IRL752 will bring to affected patients and their caregivers," says Stephan Hjorth, Ph.D., Prof., senior scientific advisor at IRLAB.

JPET, The Journal of Pharmacology and Experimental Therapeutics, is a highly ranked international research journal in the field of pharmacology. The journal is published by The American Society for Pharmacology and Experimental Therapeutics (ASPET).

IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls). The paper reports the pharmacological profile of IRL752, characterized by facilitatory impact on cortical noradrenaline, dopamine and acetylcholine neurotransmission, accompanied by improved cognitive functions. This pharmacological profile is in line with the potential clinical usefulness of IRL752 in conditions where cortical neurotransmission may be dysregulated, such as the axial motor and cognitive deficits associated with impaired balance and falls in Parkinson's Disease. The effect profile of IRL752 was characterized through in vivo studies, assessing effects on behavior, neurotransmission and gene expression, as well as in vitro assays investigating receptor interactions.

The paper was published online as part of JPET Fast Forward, which contains papers in manuscript form that have been accepted and published in JPET but have not been copyedited and have not been assigned to an issue of the journal. Copyediting, including graphics, may lead to some differences between the Fast Forward version and the final version.

Paper: Hjorth, S. et al. (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) - a novel cortical-preferring catecholamine transmission- and cognition-promoting agent. Journal of Pharmacology and Experimental Therapeutics, DOI: 10.1124/jpet.120.000037 (http://jpet.aspetjournals.org/content/early/2020/06/30/jpet.120.000037).

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

About IRL752

IRL752, one of IRLAB's two drug candidates in Phase II, is being developed for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease. The results from the clinical Phase IIa study indicate that IRL752 has the potential to improve balance and reduce the risk of falls. IRL752 has the ability to increase the levels of the neurotransmitters norepinephrine and dopamine in the frontal cortex and activate specific genes involved in nerve cell connections. In clinical research, it has been shown that the neurotransmitters noradrenaline and dopamine are decreased in the frontal cortex in Parkinson's disease. The effects of this reduction could be counteracted by treatment with IRL752 and then lead to improvement of balance, cognitive and psychiatric symptoms for these patients. A Phase IIb study with the drug candidate is planned to begin in 2020 to evaluate the effects of IRL752 on fall rate as compared to placebo.


IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and IRL752, both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North Premier Growth Market is FNCA Sweden AB, info@fnca.se, +46 (0)8528 00 399. More information on www.irlab.se. 



(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
08/03IRLAB THERAPEUTICS PUBL : IRL752 is proposed pirepemat as a unique INN by WHO
08/03IRLAB THERAPEUTICS PUBL : IRL752 is proposed pirepemat as a unique INN by WHO
07/09IRLAB THERAPEUTICS PUBL : clinical drug candidate IRL752 published in JPET
06/24IRLAB THERAPEUTICS PUBL : mesdopetam featured on cover of top-tier publication J..
06/04IRLAB THERAPEUTICS PUBL : Phase IIb/III study in Parkinson's disease to target G..
05/07IRLAB THERAPEUTICS PUBL : Report from the Annual General Meeting of IRLAB Therap..
05/06IRLAB THERAPEUTICS PUBL : clinical drug candidate mesdopetam published in JPET
04/07IRLAB THERAPEUTICS PUBL : publishes the annual report for 2019
03/23IRLAB THERAPEUTICS PUBL : Phase IIa study with IRL752 is published in Movement D..
02/27IRLAB THERAPEUTICS PUBL : rights issue oversubscribed
More news
Sales 2019 0,37 M 0,04 M 0,04 M
Net income 2019 -96,1 M -11,0 M -11,0 M
Net cash 2019 106 M 12,1 M 12,1 M
P/E ratio 2019 -15,5x
Yield 2019 -
Capitalization 1 416 M 162 M 162 M
EV / Sales 2018 12 332x
EV / Sales 2019 3 957x
Nbr of Employees -
Free-Float 99,8%
Duration : Period :
IRLAB Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRLAB THERAPEUTICS AB (PUB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts
Average target price
Last Close Price 28,75 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Nicholas Waters Chief Executive Officer
Gunnar Olof Olsson Chairman
Erik Viktor Siewertz Chief Financial Officer
Clas Sonesson Chief Scientific Officer
Joakim Tedroff Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.01%387 947
ROCHE HOLDING AG3.31%300 745
PFIZER, INC.-2.12%213 028
MERCK & CO., INC.-9.25%208 339
NOVARTIS AG-15.79%185 171